Health Systems Product News

Published Online: Thursday, January 1, 2009
Follow Pharmacy_Times:

Treanda (bendamustine hydrochloride) for Injection

Cephalon Inc (Frazer, PA) recently received FDA approval for Treanda for the treatment of patients with indolent B-cell non-Hodgkin's lymphoma (NHL) that has progressed during or within 6 months of treatment with rituximab or a rituximab-containing regimen. Treanda has a convenient dosing schedule as a treatment for indolent NHL. An intravenous infusion takes 60 minutes and can be administered in an outpatient setting, reducing the time it takes for patients to be treated. The recommended dose for indolent NHL is 120 mg/m2 administered on days 1 and 2 of a 21-day cycle, for up to 8 cycles. The product also is indicated for the treatment of patients with chronic lymphocytic leukemia, a slowly progressing blood and bone marrow disease. For more information, call 800-896- 5855, or visit www.cephalon.com.


Cardene I.V. (nicardipine hydrochloride)

EKR Therapeutics Inc (Bedminster, NJ) recently received FDA approval for double concentration of Cardene I.V. premixed injection. These patented 200-mL ready-to-use intravenous (IV) bags contain 40 mg of the calcium channel blocker nicardipine hydrochloride (0.2 mg/mL) in either dextrose or sodium chloride. In August 2008, the FDA approved a single concentration of Cardene I.V. ready-to-use IV bags. The single concentration consists of 200-mL premixed bags containing 20 mg of nicardipine hydrochloride (0.1 mg/mL) in either dextrose or sodium chloride. The product is indicated for the short-term treatment of hypertension when oral therapy is not feasible or desirable. Cardene I.V. dosage must be individualized depending on the severity of hypertension and the response of the patient during dosing. Blood pressure should be monitored both during and after the infusion. For more information, visit www.cardeneiv.com, or call 877-207-5802.


DoseTrac Infusion Management Software

B. Braun Medical Inc (Bethlehem, PA) recently launched DoseTrac Infusion Management Software with Inbound Admission, Discharge, and Transfer (ADT) Interface capabilities. The ADT Interface capability makes connectivity easier and less expensive. It is one of a series of connectivity programs the company expects to introduce for DoseTrac to support better communication among clinical, administrative, and ancillary applications. DoseTrac with ADT Interface receives real-time notification of patient arrivals, movements, and departures to help improve the efficiency of the services provided by clinicians. In-depth patient information and locations are received and posted in real time to specific views and reports within DoseTrac to help health care professionals better interpret and make use of infusion information. For more information, call 800-227-2862, or visit www.bbraunusa.com.


Rocuronium Bromide Injection

Teva Pharmaceuticals (North Wales, PA) recently received FDA approval for Rocuronium Bromide Injection. The product is AP-rated to Organon USA Inc's Zemuron. The product is a nondepolarizing neuromuscular blocking agent indicated as an adjunct to general anesthesia to facilitate both rapid sequence and routine tracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation. Rocuronium Bromide Injection is for intravenous use only. The product should only be administered by experienced clinicians or trained individuals supervised by an experienced clinician familiar with use, actions, characteristics, and complications of neuromuscular blocking agents. Doses of Rocuronium Bromide Injection should be individualized, and a peripheral nerve stimulator should be used to monitor drug effect, need for additional doses, adequacy of spontaneous recovery or antagonism, and to decrease the complications of overdosage if additional doses are administered. The product is available in multiple-dose glass vials of 5 mL, containing 50 mg Rocuronium Bromide (10 mg/mL), and 10 mL containing 100 mg Rocuronium Bromide (10 mg/mL). For more information, call 888-TEVA USA (888-838-2872), or visit www.tevausa.com.

Find it Online

For more Hospital Product News, visit www.PharmacyTimes.com/HospitalProducts




Related Articles
No Result Found
Latest Issues
$auto_registration$